EICHOR
● Recruiting
Assessing Iparomlimab and Tuvonralimab in Recurrent or Metastatic MSI-H/dMMR Gastric Cancer
Condition: Gastric / Gastroesophageal Junction Adenocarcinoma · MSI-H Cancer · Sponsor: Peking University
About this study
A randomized controlled phase II study exploring first-line treatment options for recurrent/metastatic MSI-H gastric cancer
This description comes directly from the study's public registry record.
Talk to the study team
Lin Shen · （86）10-88196561 · linshenpku@163.com
Always discuss trial participation with your own doctor first.
Locations (10)
| The Fourth Hospital of Hebei Medical University | Shijiazhuang, Hebei, China | Recruiting |
| Harbin Medical University Cancer Hospital | Harbin, Heilongjiang, China | Recruiting |
| The First Affiliated Hospital of Zhengzhou University | Zhengzhou, Henan, China | Recruiting |
| Jiangsu Provincial People's Hospital | Nanjing, Jiangsu, China | Recruiting |
| The First Affiliated Hospital of Xi'an Jiao Tong University） | Xi'an, Shaanxi, China | Recruiting |
| The Affiliated Hospital of Qingdao University | Qingdao, Shandong, China | Recruiting |
| Shanxi Cancer Hospital | Taiyuan, Shanxi, China | Recruiting |
| West China Hospital, Sichuan University | Chengdu, Sichuan, China | Recruiting |
| Tianjin Medical University Cancer Institute & Hospital | Tianjin, Tianjin Municipality, China | Recruiting |
| Department of GI Oncology, Peking University Cancer Hospital | Beijing, China | Recruiting |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07127822